4g3y Citations

Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.

J. Biol. Chem. 288 13799-807 (2013)
Cited: 19 times
EuropePMC logo PMID: 23504311

Abstract

Background

Although infliximab has high efficacy in treating TNFα-associated diseases, the epitope on TNFα remains unclear.

Results

The crystal structure of the TNFα in complex with the infliximab Fab is reported at a resolution of 2.6 Å.

Articles - 4g3y mentioned but not cited (2)

  1. Improving B-cell epitope prediction and its application to global antibody-antigen docking. Krawczyk K, Liu X, Baker T, Shi J, Deane CM. Bioinformatics 30 2288-2294 (2014)
  2. In silico analysis of single nucleotide polymorphism (SNP) in human TNF-α gene. Dabhi B, Mistry KN. Meta Gene 2 586-595 (2014)


Reviews citing this publication (3)

  1. Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. Soleimanpour S, Hassannia T, Motiee M, Amini AA, Rezaee SA. Crit. Rev. Biotechnol. 37 371-392 (2017)
  2. Fc fusion as a platform technology: potential for modulating immunogenicity. Levin D, Golding B, Strome SE, Sauna ZE. Trends Biotechnol. 33 27-34 (2015)
  3. Current approaches to fine mapping of antigen-antibody interactions. Abbott WM, Damschroder MM, Lowe DC. Immunology 142 526-535 (2014)

Articles citing this publication (14)

  1. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, Guo Y, Lou Z. J. Biol. Chem. 288 27059-27067 (2013)
  2. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. Ann. Rheum. Dis. 74 311-314 (2015)
  3. Dimerization of LTβR by LTα1β2 is necessary and sufficient for signal transduction. Sudhamsu J, Yin J, Chiang EY, Starovasnik MA, Grogan JL, Hymowitz SG. Proc. Natl. Acad. Sci. U.S.A. 110 19896-19901 (2013)
  4. Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing. Kowalsky CA, Faber MS, Nath A, Dann HE, Kelly VW, Liu L, Shanker P, Wagner EK, Maynard JA, Chan C, Whitehead TA. J. Biol. Chem. 290 26457-26470 (2015)
  5. Rational design of antirheumatic prodrugs specific for sites of inflammation. Onuoha SC, Ferrari M, Sblattero D, Pitzalis C. 67 2661-2672 (2015)
  6. Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange. van Schie KA, Ooijevaar-de Heer P, Dijk L, Kruithof S, Wolbink G, Rispens T. Sci Rep 6 32747 (2016)
  7. B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera. Homann A, Röckendorf N, Kromminga A, Frey A, Jappe U. J Transl Med 13 339 (2015)
  8. Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure. Chen K, Long DS, Lute SC, Levy MJ, Brorson KA, Keire DA. J Pharm Biomed Anal 128 398-407 (2016)
  9. Molecular modeling of antibodies for the treatment of TNFα-related immunological diseases. Pierri CL, Bossis F, Punzi G, De Grassi A, Cetrone M, Parisi G, Tricarico D. Pharmacol Res Perspect 4 e00197 (2016)
  10. Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins. Andrick BJ, Schwab AI, Cauley B, O'Donnell LA, Meng WS. PLoS ONE 10 e0135451 (2015)
  11. In silico studies for the interaction of tumor necrosis factor-alpha (TNF-α) with different saponins from Vietnamese ginseng (Panax vietnamesis). Kim OT, Le MD, Trinh HX, Nong HV. Biophys Physicobiol 13 173-180 (2016)
  12. Infliximab crystal structures reveal insights into self-association. Lerch TF, Sharpe P, Mayclin SJ, Edwards TE, Lee E, Conlon HD, Polleck S, Rouse JC, Luo Y, Zou Q. MAbs 9 874-883 (2017)
  13. Comparative in silico analyses of Cannabis sativa, Prunella vulgaris and Withania somnifera compounds elucidating the medicinal properties against rheumatoid arthritis. Zaka M, Sehgal SA, Shafique S, Abbasi BH. J. Mol. Graph. Model. 74 296-304 (2017)
  14. Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis. Wang Y, van Assen AHG, Reis CR, Setroikromo R, van Merkerk R, Boersma YL, Cool RH, Quax WJ. FEBS J. 284 2501-2512 (2017)